# A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

> **NCT01309412** · PHASE1 · TERMINATED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 9 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Siltuximab

## Key facts

- **NCT ID:** NCT01309412
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Protocol was stopped due to the safety issue in Global
- **Last updated:** 2014-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01309412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01309412, "A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01309412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*